Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.

Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.

<h4>Background</h4>Rising resistance of HIV-1 to non-nucleoside reverse transcriptase inhibitors (NNRTIs) threatens the success of the global scale-up of antiretroviral therapy (ART). The switch to WHO-recommended dolutegravir (DTG)-based regimens could reduce this threat due to DTG'...

Full description

Bibliographic Details
Main Authors:	Anthony Hauser, Katharina Kusejko, Leigh F Johnson, Huldrych F Günthard, Julien Riou, Gilles Wandeler, Matthias Egger, Roger D Kouyos
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2020-12-01
Series:	PLoS Medicine
Online Access:	https://doi.org/10.1371/journal.pmed.1003397

Similar Items

Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in South Africa.
by: Anthony Hauser, et al.
Published: (2019-06-01)

HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling
by: Reneé de Waal, et al.
Published: (2018-11-01)

O papel do dolutegravir na terapia antiretroviral
by: Tamyres dos Santos Vieira, et al.
Published: (2019-06-01)

Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis [version 1; referees: 3 approved]
by: Gilles Wandeler, et al.
Published: (2018-08-01)

Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis [version 2; peer review: 3 approved]
by: Gilles Wandeler, et al.
Published: (2019-04-01)

Dolutegravir and the universal antiretroviral regimen: good may be the enemy of perfect
by: Reuben Granich, et al.
Published: (2018-05-01)

Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
by: Delphine Sculier, et al.
Published: (2020-11-01)

Phylodynamics on local sexual contact networks.
by: David A Rasmussen, et al.
Published: (2017-03-01)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV.
by: Analú Correa, et al.
Published: (2020-01-01)

Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients
by: Yogesh Suresh Punekar, et al.
Published: (2019-12-01)

Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link
by: Huyen Nguyen, et al.
Published: (2021-06-01)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
by: Kairoonisha Mahomed, et al.
Published: (2020-07-01)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
by: Dario Cattaneo, et al.
Published: (2020-03-01)

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation
by: Dominique L. Braun, et al.
Published: (2020-11-01)

Monitoring of antiretroviral therapy and mortality in HIV programmes in Malawi, South Africa and Zambia: mathematical modelling study.
by: Janne Estill, et al.
Published: (2013-01-01)

Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy
by: Michelle A. Moorhouse, et al.
Published: (2018-10-01)

A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA.
by: Gilles Wandeler, et al.
Published: (2011-01-01)

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
by: Rebecca Zash, MD, et al.
Published: (2018-07-01)

Evaluation of urinary excretion of dolutegravir or emtricitabine/tenofovir/elvitegravir/cobicistat antiretroviral-based regimens using plasma and urine trough concentration
by: Jérémy Lourenco, et al.
Published: (2018-05-01)

Suicidal overdose of dolutegravir: A case report
by: Rahul Daimari, et al.
Published: (2018-06-01)

Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: A mathematical modelling study.
by: Leigh F Johnson, et al.
Published: (2017-12-01)

Access to antiretroviral treatment in South Africa, 2004 - 2011
by: Leigh Francis Johnson
Published: (2012-03-01)

Retention in care of HIV-infected children from HIV test to start of antiretroviral therapy: systematic review.
by: Catrina Mugglin, et al.
Published: (2013-01-01)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
by: Dowers E, et al.
Published: (2018-11-01)

Which antiretroviral regimen is associated with higher adherence in Brazil? A comparison of single, multi, and dolutegravir-based regimens
by: Tarsilla Spezialli Cardoso, et al.

Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis.
by: Mario Cruciani, et al.
Published: (2019-01-01)

Assessing the potential impact of transmission during prolonged viral shedding on the effect of lockdown relaxation on COVID-19.
by: Burcu Tepekule, et al.
Published: (2021-01-01)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
by: Zamora FJ, et al.
Published: (2019-10-01)

The role of dolutegravir in the management of HIV infections
by: Miller MM, et al.
Published: (2015-02-01)

Enhanced Eryptosis Following Exposure to Dolutegravir
by: Abdulla Al Mamun Bhuyan, et al.
Published: (2016-07-01)

DOLUTEGRAVIR efficacy in HIV infected patients
by: Dumitru Irina Magdalena, et al.
Published: (2015-02-01)

Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir
by: Laura Campogiani, et al.
Published: (2019-07-01)

Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings
by: Emmanuel Ndashimye, et al.
Published: (2021-04-01)

Progress towards the 2020 targets for HIV diagnosis and antiretroviral treatment in South Africa
by: Leigh F. Johnson, et al.
Published: (2017-07-01)

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
by: Cecilia L. Moore, et al.
Published: (2021-01-01)

Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV.
by: Katharina Kusejko, et al.
Published: (2020-12-01)

Creation of a long-acting nanoformulated dolutegravir
by: Brady Sillman, et al.
Published: (2018-02-01)

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS
by: Taha H, et al.
Published: (2015-10-01)

Systematic De-escalation of Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus Emtricitabine or Lamivudine in Swiss HIV-positive Persons
by: Natascha D. Diaco, et al.
Published: (2018-12-01)

Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy
by: Guan-Jhou Chen, et al.
Published: (2021-04-01)